Markedly Elevated Levels of Vascular Endothelial Growth Factor in Malignant Ascites

AbstractBackground: Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that also has the ability to increase vascular permeability. Malignant ascites has significant morbidity, but the mechanism of its development is unknown. Because of the permeability-inducing properties of VEGF, we hypothesized that malignant ascites formation is associated with high levels of VEGF. The purpose of our study was to determine the role of VEGF in malignant ascites formation. Methods: Ascites from 25 patients with gastric (n = 6), colon (n = 7), or ovarian (n = 12) cancers was collected by paracentesis or surgery. VEGF protein levels were determined by enzyme-linked immunosorbent assay. The effect of ascites on endothelial cell permeability was assessed by evaluating propidium iodide uptake by human umbilical vein endothelial cells (HUVECs) exposed to ascites. Neutralizing antibodies to VEGF added to ascites were used to determine the causal effect of VEGF in permeability induction. Results: VEGF protein levels were markedly increased in malignant ascites compared with levels in nonmalignant cirrhotic ascites (controls). VEGF protein levels in ovarian, gastric, and colon cancer ascites were found to be increased 45, 23, and 12 times, respectively, compared with levels in cirrhotic ascites. Malignant ascites from patients with colon and gastric cancer caused an increase in permeability in HUVECs in all cases. Neutralizing VEGF activity in colon cancer ascites decreased in-vitro HUVEC permeability in three of four cases. Conclusions: VEGF protein levels are markedly elevated in malignant ascites. VEGF may play a role in malignant ascites formation by increasing endothelial cell permeability.

[1]  L. Ellis,et al.  Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  H. D. Kuntz.  ["Malignant" ascites]. , 1981, MMW, Munchener medizinische Wochenschrift.

[3]  J. Schölmerich,et al.  Evidence for the production of high amounts of interleukin-6 in the peritoneal cavity of patients with ascites. , 1992, Journal of hepatology.

[4]  J. Schenker,et al.  Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. , 1997, Fertility and sterility.

[5]  E. Manseau,et al.  Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. , 1993, The American journal of pathology.

[6]  K. Shitara,et al.  Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. , 1998, Cancer research.

[7]  Y. Liaw,et al.  Serum—ascites albumin concentration gradient and ascites fibronectin in the diagnosis of malignant ascites , 1992, Cancer.

[8]  H. Dvorak,et al.  Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. , 1993, Cancer research.

[9]  J. Schölmerich,et al.  High concentrations of soluble tumor necrosis factor receptors in ascites , 1992, Hepatology.

[10]  Y. Meng,et al.  Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. , 1996, The Journal of clinical endocrinology and metabolism.

[11]  G. Bastert,et al.  Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. , 1991, European journal of cancer.

[12]  A. Gerbes,et al.  Pathophysiology of elevated ascites fluid cholesterol in malignant ascites. Increased ascites to serum relation of proteins and lipoproteins in patients with peritoneal carcinomatosis as compared to patients with cirrhosis of the liver. , 1992, Journal of hepatology.

[13]  L. Ellis,et al.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. , 1995, Cancer research.

[14]  D. Charnock-Jones,et al.  Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. , 1995, Journal of the National Cancer Institute.

[15]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[16]  R. N. Garrison,et al.  Malignant Ascites: Clinical and Experimental Observations , 1986, Annals of surgery.

[17]  G. Haines,et al.  Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. , 1994, Journal of immunology.

[18]  R. Steele,et al.  Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. , 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[19]  L. Ellis,et al.  Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. , 1997, Archives of surgery.

[20]  A. Goldfien,et al.  Sera From Preeclamptic Women Specifically Activate Human Umbilical Vein Endothelial Cells In Vitro: Morphological and Biochemical Evidence , 1992, American journal of reproductive immunology.

[21]  E. Manseau,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. , 1993, Cancer research.

[22]  T. Tamaya,et al.  Induction of endogenous tumor necrosis factor by OK-432 in ovarian cancer patients with ascites , 1989, Biotherapy.

[23]  G. Zientara,et al.  Exchange of macromolecules between plasma and peritoneal cavity in ascites tumor-bearing, normal, and serotonin-injected mice. , 1989, Cancer research.

[24]  J. Winer,et al.  The vascular endothelial growth factor family of polypeptides , 1991, Journal of cellular biochemistry.

[25]  J. Rüschoff,et al.  Tumor necrosis factor effects on ascites formation in an experimental tumor model. , 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[26]  D. Connolly,et al.  Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo , 1993, British journal of pharmacology.